Immune-mediated pathology in Duchenne muscular dystrophy. - Wikidata - wikimedia - TriplyDB

Immune-mediated pathology in Duchenne muscular dystrophy.

Immune-mediated pathology in Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q38561435

about

A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy.Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.Tissue Tregs.Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy).Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up.Targeting early PKCθ-dependent T-cell infiltration of dystrophic muscle reduces disease severity in a mouse model of muscular dystrophy.Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.1 H NMRS of carnosine combined with 31 P NMRS to better characterize skeletal muscle pH dysregulation in Duchenne muscular dystrophy.Proteomic profiling of the dystrophin complex and membrane fraction from dystrophic mdx muscle reveals decreases in the cytolinker desmoglein and increases in the extracellular matrix stabilizers biglycan and fibronectin.Elevated phosphodiester and T2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients.Increased Number of Circulating CD8/CD26 T Cells in the Blood of Duchenne Muscular Dystrophy Patients Is Associated with Augmented Binding of Adenosine Deaminase and Higher Muscular Strength Scores.Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice.Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry.Effect of Ibuprofen on Skeletal Muscle of Dysferlin-null Mice.A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy.MicroRNA-206 Downregulation Improves Therapeutic Gene Expression and Motor Function in mdx Mice.Necroptosis mediates myofibre death in dystrophin-deficient mice Drug Repurposing for Duchenne Muscular Dystrophy: The Monoamine Oxidase B Inhibitor Safinamide Ameliorates the Pathological Phenotype in Mice and in Myogenic Cultures From DMD Patients

P2860

Q33625958-E61AF689-7801-45E9-8F81-D9CA1F3DF5A5 Q33675040-A4D65928-E033-4D0A-870D-76B537D316F9 Q33809437-BA923B70-7E79-47AC-A8A5-65A726C5C84F Q37088061-BC51E2F4-486A-46F3-829D-376973F8B88E Q37367980-AC2B1F82-0E2A-45C6-8654-741DEA390383 Q37396900-D59B31DF-83D6-43CC-BBCE-496017CCC0A0 Q38649230-1C2428FB-9D73-4464-8A59-24998500157A Q47320981-5950607F-7E39-44F9-9283-E686F46745A6 Q47337769-A31174C7-2D09-429F-BDD8-6E9412A27CCC Q47606957-6232252A-A26A-4456-9351-597DE0947A12 Q47609659-BBD94893-C211-4DF4-9EC6-9121352EEBAB Q47959546-92DC138A-7A2E-4057-B42D-E07B2D2B9C9A Q48217628-E2024D4C-B958-4175-A0AA-E068707BFECD Q49220622-1E9657DB-A76A-485F-B2A2-4CF4542D3A5F Q49644555-A16A7068-AE1C-4FD1-9DBE-83AEDBFE57C2 Q50079558-D1D45F12-2272-4DCB-BBD0-E85F83AFBEE5 Q50128178-5A8BE57C-1AB2-4B6C-9E4C-330A10782AE6 Q50133251-64507A3A-DF15-451A-8716-8FE6C4B7E80A Q55340374-A3B00A5C-7933-4696-8DE2-DF9942ED0A82 Q58759838-38DD3747-D969-4BAC-BE95-153D1B911DE1 Q58781307-250DA4E6-DE79-4580-A403-A8FAC7D1A551

P2860

Immune-mediated pathology in Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q38561435

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Immune-mediated pathology in Duchenne muscular dystrophy.

@en

type

label

Immune-mediated pathology in Duchenne muscular dystrophy.

@en

prefLabel

Immune-mediated pathology in Duchenne muscular dystrophy.

@en

P1433

Q38561435-A8F104B0-5D1F-4D5D-9ECF-B31C774BA9C8

P1476

Q38561435-F0A607DA-E2BB-4366-A704-0DB23F735523

P2093

Q38561435-098CF08D-2C7D-47DE-A5BB-3E4526AAC6C6

Q38561435-4F760389-43A9-4B6B-AC88-5D80174155AA

Q38561435-868181D2-ADAB-4A92-9D3F-DBA3B481601E

Q38561435-B0418463-2652-4E2C-814F-F742ED6FB0D9

Q38561435-D7BE6E91-0B6E-4D44-A1A9-0E13B6C39686

Q38561435-ED7EDF95-4EBD-4B6A-8357-069220D3EBF0

Q38561435-F7F472E6-0903-417B-9001-260DF3A0EC78

P2860

Q38561435-035D742D-C895-4FD5-BA6F-378110858C35

Q38561435-071148F0-B6AB-4410-B2AA-111301DB20CC

Q38561435-146D7F18-BE2E-4973-A72C-5011155BD30F

Q38561435-19F5EEA2-744E-4905-AC10-4DF73C7EE094

Q38561435-201E241E-B763-496E-A3D1-DD500A458700

Q38561435-20833509-1430-4711-815F-10AB3A8430A0

Q38561435-22B234A6-4653-4CAC-B358-C0B66C7B5B7E

Q38561435-2B3D8CC5-642A-4118-82CC-EC95120CD184

Q38561435-2D43974F-C131-4081-8F09-989449D4CD67

Q38561435-2E33BFBF-2045-44F9-AE3B-D26AC2CA237A

P304

Q38561435-6CD320FD-8DFE-44C3-862E-807CFF6D6D29

P31

Q38561435-D3C6D450-5DFA-43FC-AE2B-C9A1E3D7FE85

P356

Q38561435-44EEBE35-ECB1-44B0-BDE6-F43F8F980B82

P407

Q38561435-35544146-2BAE-47A1-A88D-F1B55386318D

P433

Q38561435-823BCB20-0E96-41B1-AF64-BB207C37DE92

P478

Q38561435-08F9C0D6-0FB0-4A19-BB1B-0C8FBAF62427

P50

Q38561435-0484393C-D614-4179-A146-1A519D77C52D

P577

Q38561435-2584656E-7C68-48FE-A839-754A069085C9

P698

Q38561435-76D74956-06B2-4F6F-BCD7-0C0F85D75C23

P932

Q38561435-BCAE5C16-E340-45FD-AB8B-B85A74F84320

P356

SCITRANSLMED.AAA7322

P1433

Science Translational Medicine

P1476

Immune-mediated pathology in Duchenne muscular dystrophy.

@en

P2093

Amy S Rosenberg

http://www.w3.org/2001/XMLSchema#string

Eric P Hoffman

http://www.w3.org/2001/XMLSchema#string

Janet Woodcock

http://www.w3.org/2001/XMLSchema#string

Lalage M Wakefield

http://www.w3.org/2001/XMLSchema#string

Montserrat Puig

http://www.w3.org/2001/XMLSchema#string

S Armando Villalta

http://www.w3.org/2001/XMLSchema#string

V Ashutosh Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies

Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta

Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophy

Complexities of TGF-β targeted cancer therapy.

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

Antifibrotic activities of pirfenidone in animal models

Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro

General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP)

P304

299rv4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAA7322

http://www.w3.org/2001/XMLSchema#string

P407

P433

299

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Kanneboyina Nagaraju

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26246170

http://www.w3.org/2001/XMLSchema#string

P932

5951380

http://www.w3.org/2001/XMLSchema#string